Hantavirus Entry Point Mapped in New Study
Researchers identify how the virus attaches to human cells, a step toward antivirals that do not yet exist.
Updated on Nov. 5, 2026 in COVID-19
Scientists have revealed the structure of protocadherin-1 (PCDH1), a cell-surface receptor that New World hantaviruses use to enter host cells, bound to the Andes virus spike. The work also shows that four neutralising antibodies can block receptor binding through two distinct mechanisms. No approved therapeutics currently exist for hantaviruses, so the findings are early-stage laboratory research relevant to future antiviral development worldwide.
Why it matters
Hantaviruses cause serious illness and currently have no approved treatments, so a detailed map of how the virus attaches to human cells gives researchers a concrete target. Knowing exactly how the receptor fits the viral spike is a foundational step toward designing drugs or antibody-based approaches that could block infection.
The findings come from structural biology work combining near-atomic-resolution imaging, mutagenesis experiments, and functional testing of four neutralising antibodies. This is laboratory research, not clinical testing, and it has not yet been shown to work in patients.
The details
PCDH1 binds asymmetrically inside a deep central pocket formed by four Gn protomers in the viral spike, a recessed site that explains why the receptor only recognizes intact viral particles or soluble tetramers rather than isolated fragments. Mutagenesis experiments identified three Gn loops that shape this receptor-binding site. Because these structural features can transfer PCDH1 binding from New World to Old World hantavirus glycoproteins, the mechanism may be broadly shared across hantavirus types. Some of the tested antibodies physically occluded access to the PCDH1-binding site, while others blocked receptor engagement through steric interference.
Timeline
Nature study on PCDH1 and hantavirus structure published online ahead of print in 2026
Health Landscape
Hantaviruses have no approved therapeutics, leaving antiviral development at an early, structure-driven stage. Mapping how viral spikes engage host receptors is a common first step in designing drugs and antibodies for emerging viral threats.
For most readers this is early research that will not change care today, and no hantavirus treatment is yet available. Anyone with concerns about hantavirus exposure, such as through rodent contact during travel or work in rural areas, should discuss prevention and symptoms with a physician.
The takeaway
Hantavirus research has moved toward a detailed molecular map of how the virus enters cells, which is what future antiviral design depends on. Preventing exposure to rodents and their droppings remains the most practical step, and questions about hantavirus risk are best raised with a healthcare provider.
Further reading
For broader context on how researchers study and develop treatments for emerging viruses, see our COVID-19 coverage.
Source note: This article includes information reported by European Medical Journal.
